The technology, created at Intermed Labs at Mon Health, is a software application and hardware tool that helps sacral neuromodulation. The technology aims to make peripheral nerve evaluation lead placement easier, faster and more accurate, according to a May 1 press release from Mon Health.
The terms of the acquisition were not disclosed, but Mon Health expects it to receive FDA clearance and be commercially available in mid-2024.
